Edition:
United States

Morphosys AG (MORG.DE)

MORG.DE on Xetra

56.52EUR
8:47am EDT
Change (% chg)

€-0.68 (-1.19%)
Prev Close
€57.20
Open
€56.83
Day's High
€56.93
Day's Low
€56.17
Volume
76,781
Avg. Vol
172,226
52-wk High
€68.73
52-wk Low
€35.61

Latest Key Developments (Source: Significant Developments)

Morphosys affirms guidance after Q2 results
Thursday, 3 Aug 2017 01:00am EDT 

Aug 3 (Reuters) - Morphosys Ag :dgap-news: morphosys reports significant progress in its therapeutic programs in second quarter of 2017.Says in Q2 of 2017, group revenues amounted to eur 11.7 million, comparable with revenue level in Q2 2016 (eur 12.2 million)..Says proprietary development segment recorded revenues of eur 0.3 million (Q2 2016: eur 0.2 million)..Says in partnered discovery segment Q2 revenues reached eur 11.5 million (Q2 2016: eur 12.0 million)..Says group EBIT in Q2 2017 amounted to eur -15.4 million (q2 2016: eur -9.5 million).Says continues to expect group revenues in range of eur 46 to 51 million.Says research and development expenses for proprietary drug development and technology development are confirmed to be in a corridor of eur 85 to 95 million..Says guidance for earnings before interest and taxes (EBIT) continues to be in range from eur -75 to -85 million.  Full Article

Morphosys CEO sees 5 months of guselkumab royalties this year
Friday, 14 Jul 2017 05:23am EDT 

July 14 (Reuters) - Morphosys CEO tells Reuters:Says he expects royalties for 5 months this year after U.S. Approval of guselkumab.Says milestone payment for guselkumab approval is included in FY guidance, royalties are not.  Full Article

Morphosys says Janssen received US FDA approval for Tremfya for treatment of plaque psoriasis
Thursday, 13 Jul 2017 05:10pm EDT 

July 13 (Reuters) - Morphosys Ag :Morphosys announces that its licensee janssen has received us FDA approval for Tremfya for the treatment of moderate to severe plaque Psoriasis.Licensee Janssen biotech has reported that U.S. Food and drug administration has approved Tremfya.Morphosys will receive a milestone payment from janssen in connection with BLA approval.Financial details were not disclosed.  Full Article

Morphosys presents data from phase 2 clinical trial with MOR208 in patients with DLBCL
Monday, 5 Jun 2017 09:00am EDT 

June 5 (Reuters) - MORPHOSYS AG ::MORPHOSYS PRESENTS FIRST SAFETY AND EFFICACY DATA OF MOR208 IN COMBINATION WITH LENALIDOMIDE FROM A PHASE 2 STUDY IN DLBCL.PRELIMINARY DATA SHOW AN OBJECTIVE RESPONSE IN 19 OUT OF 34 PATIENTS (ORR: 56%)..COMPLETE REMISSION WAS SEEN IN 11 OUT OF 34 PATIENTS (CR: 32%). 16 OUT OF 19 PATIENTS IN WHOM RESPONSES WERE RECORDED, WERE STILL ON STUDY AT TIME OF DATA-CUT OFF.  Full Article

Morphosys: Janssen updates on development of guselkumab
Wednesday, 24 May 2017 05:33am EDT 

May 24 (Reuters) - MORPHOSYS AG ::ANNOUNCES THAT ITS LICENSEE JANSSEN REPORTED UPDATES ON DEVELOPMENT OF GUSELKUMAB.IN ADDITION, JANSSEN ANNOUNCED PLANS FOR THREE NEW PHASE 3 CLINICAL TRIALS WITH GUSELKUMAB.  Full Article

Morphosys confirms 2017 outlook after Q1 loss widens
Wednesday, 3 May 2017 01:08am EDT 

May 3 (Reuters) - Morphosys Ag :dgap-news: morphosys ag reports solid first quarter 2017.Q1 revenue 11.8 million eur.Group revenues amounted to eur 11.8 million, in line with level of q1 of 2016.Earnings before interest and taxes (ebit) in q1 2017 stood at eur -14.9 million (q1 2016: eur - 9.7 million).In q1 2017, consolidated net result amounted to eur -15.0 million (q1 2016: eur -7.2 million).At end of q1 2017, company had a cash position of eur 349.9 million compared to eur 359.5 million.For financial year 2017, morphosys continues to expect group revenues in range of eur 46 to 51 million.Confirmed its guidance for earnings before interest and taxes (ebit) of eur -75 to -85 million.  Full Article

Morphosys chief scientific officer takes temporary leave
Thursday, 23 Mar 2017 02:30am EDT 

Morphosys AG : Says CSO Marlies Sproll takes temporary leave, Markus Enzelberger to serve as interim CSO .Says she continues to be a member of executive board and will return to her CSO role as soon as circumstances will allow.  Full Article

Morphosys reports smaller than expected 2016 EBIT loss
Thursday, 9 Mar 2017 01:00am EST 

Morphosys AG : Financial guidance for 2016 met in full . Group revenues of eur 49.7 million (guidance: eur 47 to 52 million) . EBIT of eur -59.9 million (guidance: eur -58 to -68 million) . Strong cash position of eur 359.5 million at year-end (dec. 31, 2015: eur 298.4 million) .In 2016, consolidated net result amounted to eur -60.4 million (2015: eur 14.9 million).  Full Article

Morphosys sees FY 2016 revenue eur 47-52 million
Monday, 1 Aug 2016 01:07am EDT 

Morphosys Ag :Sees fy 2016 revenue eur 47 million to eur 52 million.  Full Article

Morphosys H1 EBIT at -19.2 mln eur
Monday, 1 Aug 2016 01:07am EDT 

Morphosys Ag : Says group revenue in first half of 2016 totaled eur 24.3 million and EBIT amounted to eur -19.2 million . Says group's liquidity position on june 30, 2016 equaled eur 279.7 million (December 31, 2015: eur 298.4 million) .Says company confirms its 2016 guidance for revenue in range of eur 47 million to eur 52 million and EBIT between eur -58 million and eur -68 million..  Full Article

BRIEF-Morphosys affirms guidance after Q2 results

* dgap-news: morphosys reports significant progress in its therapeutic programs in second quarter of 2017